

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | — | 1 | — | — | — | 1 |
| Drug common name | Orelabrutinib |
| INN | orelabrutinib |
| Description | Orelabrutinib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target tyrosine-protein kinase BTK. |
| Classification | Small molecule |
| Drug class | tyrosine kinase inhibitors: tyrosine kinase inhibitors Bruton's (Btk) inhibitors |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | C=CC(=O)N1CCC(c2ccc(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)n2)CC1 |
| PDB | — |
| CAS-ID | 1655504-04-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4650321 |
| ChEBI ID | — |
| PubChem CID | 91667513 |
| DrugBank | DB16272 |
| UNII ID | WJA5UO9E10 (ChemIDplus, GSRS) |

